NEW YORK (GenomeWeb) – EKF Diagnostics today announced that it has received two new proposals regarding the sale of its point-of-care (POC) diagnostics business.
EKF said in a statement that it has received a second non-binding preliminary offer of $115 million to $125 million in cash for its POC diagnostics unit from an undisclosed third party.
In a separate statement, the firm said it has received a third non-binding preliminary proposal for the POC diagnostics business from Chinese firm Jinjing Group that may or may not lead to an offer.
The deals would not include EKF's clinical chemistry or molecular diagnostics businesses.
The Cardiff, UK-based firm announced the potential sale of its POC diagnostics business as a result of a strategic review initiated by its board in April. An undisclosed buyer has offered $110 million for the POC diagnostics business.